1. A preliminary indication that HLA-A*03:01 may be associated with visceral leishmaniasis development in people living with HIV in Ethiopia.
- Author
-
de Vrij N, Vandoren R, Ramadan K, Van Hul A, Ceulemans A, Kassa M, Melkamu R, Yeshanew A, Bogale T, Beyene H, Sisay K, Kibret A, Mersha D, Cuypers WL, Vogt F, van Henten S, Ritmeijer K, Pham TT, Meysman P, Laukens K, Cuypers B, Diro E, Mohammed R, van Griensven J, and Adriaensen W
- Subjects
- Humans, Ethiopia epidemiology, Male, Adult, Female, Genotype, Young Adult, Middle Aged, HLA-A Antigens genetics, Adolescent, Alleles, Genetic Predisposition to Disease, Leishmaniasis, Visceral epidemiology, HIV Infections complications, HIV Infections epidemiology, Coinfection epidemiology
- Abstract
Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. VL-HIV often leads to high rates of antileishmanial treatment failure and recurrent VL disease relapses. Considering the high prevalence of HIV and Leishmania in the Ethiopian population, preventing the progression of asymptomatic Leishmania infection to disease would be a valuable asset to VL disease control and to the clinical management of people living with HIV (PLWH). However, such a strategy requires good understanding of risk factors for VL development. In immunocompetent individuals living in Brazil, India, or Iran, the Human Leukocyte Antigen (HLA) gene region has been associated with VL development. We used NanoTYPE, an Oxford Nanopore Technologies sequencing-based HLA genotyping method, to detect associations between HLA genotype and VL development by comparing 78 PLWH with VL history and 46 PLWH that controlled a Leishmania infection, all living in a VL endemic region of North-West Ethiopia. We identified an association between HLA-A*03:01 and increased risk of VL development (OR = 3.89). These data provide candidate HLA alleles that can be further explored for inclusion in a potential Leishmania screen-and-treat strategy in VL endemic regions., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: W.A. received a travel grant by Omixon to participate in the European Federation for Immunogenetics conference to present the preliminary results of this work. Omixon had no role in study design, data collection and analysis, preparation of the manuscript, nor the decision to publish., (Copyright: © 2024 de Vrij et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF